Sanofi ends development of amcenestrant breast cancer treatment

PARIS — French healthcare company Sanofi on Wednesday said it would end the development program of amcenestrant, an estrogen receptor degrader aimed at curing breast cancer. The drugmaker said the drug “did not meet the prespecified boundary for continuation in comparison with the control arm and recommended stopping the trial.” (Reporting by Tassilo Hummel, editing […]